Differences of Clinical Disease Activity Index (CDAI) in Rheumatoid Arthritis Patients Towards the Use of Disease Modifying Anti Rheumatic Drugs (DMARD)
- DOI
- 10.2991/ahsr.k.211105.018How to use a DOI?
- Keywords
- rheumatoid arthritis; therapy; DMARD; CDAI
- Abstract
Rheumatoid arthritis is an autoimmune disease commonly associated with progressive disability and systemic complications. Rheumatoid arthritis is characterized by inflammation and synovial hyperplasia, production of autoantibodies, and destruction of bone and cartilage. One of the assessments of rheumatoid arthritis disease activity is Clinical Disease Activity Index (CDAI). Rheumatoid arthritis can be prevented with a right therapy. One of the main therapies for rheumatoid arthritis is Disease Modifying Antirheumatic Drugs (DMARD). This study aims to determine the patient’s sociodemographic characteristics, to see the pattern of drug use, and to determine the difference in the CDAI value before and after medication is given. This research is a descriptive and analytic study, with a retrospective approach. There were 61 patients who entered the inclusion criteria. The results showed that the most rheumatoid arthritis patients who received DMARD therapy were women (96.72%), among which aged 46-55 years (31.1%). From these women, 49.2% graduated from high schools and 45.9% were housewives. In the pattern of DMARD use, the presentation of DMARD monotherapy was 11.5%, the combination of DMARD and corticosteroid was 21.3%, the combination of DMARD and NSAID was 4.9%, and the combination of DMARD, corticosteroid, and NSAID was 62.3%. The highest DMARD use was methotrexate with a percentage of 62.3%. The findings conclude that there is a significant difference in the value of CDAI before and after DMARD was given in rheumatoid arthritis patients at Dr. M. Djamil Padang hospital, both on the use of DMARD monotherapy, combination of DMARD and corticosteroid, combination of DMARD and NSAID, and combination of DMARD, corticosteroid and NSAID. The average CDAI value after DMARD therapy was smaller than before treatment.
- Copyright
- © 2021 The Authors. Published by Atlantis Press International B.V.
- Open Access
- This is an open access article under the CC BY-NC license.
Cite this article
TY - CONF AU - Rahmi Yosmar AU - Sindi Suija AU - Yoneta Srangenge AU - A. Almahdy PY - 2021 DA - 2021/11/17 TI - Differences of Clinical Disease Activity Index (CDAI) in Rheumatoid Arthritis Patients Towards the Use of Disease Modifying Anti Rheumatic Drugs (DMARD) BT - Proceedings of the 2nd International Conference on Contemporary Science and Clinical Pharmacy 2021 (ICCSCP 2021) PB - Atlantis Press SP - 125 EP - 129 SN - 2468-5739 UR - https://doi.org/10.2991/ahsr.k.211105.018 DO - 10.2991/ahsr.k.211105.018 ID - Yosmar2021 ER -